NCT05544058Completed
Retrospective Non-interventional Study of Stiripentol Use in Dravet Patients in the USA
Source: ClinicalTrials.gov · Last updated 2 Aug 2024
Brief summary (registry, in English)
The present study aims to collect data regarding the history of the disease, previous and current treatments, and the clinical status of Dravet patients during the 3 months prior to stiripentol initiation, the first 3 months on stiripentol and the last 3 months on stiripentol (irrespective of stiripentol discontinuation).
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 100 (actual)
- First submitted
- 24 Aug 2022
- Start date
- 27 Apr 2022
- Primary completion date
- 28 Jun 2024
- Lead sponsor
- Biocodex
- Diseases
- Epilepsy
- NCT number
- NCT05544058
What you commit to
- Study type: Observational
- Participants enrolled: 100
- From 27 Apr 2022 to the primary completion date, 28 Jun 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- NA
Who the study is looking for
- Patients diagnosed with Dravet syndrome
- Treated with stiripentol for a minimum of 3 months in routine practice
Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mayo Clinic Coordinator of this site? Confirm its status | Rochester | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.